No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CALT240517P12500
- 0.15
- 0.000.00%
15min DelayClose May 9 10:38 ET
0.00High0.00Low
0.15Open0.15Pre Close0 Volume20 Open Interest12.50Strike Price0.00Turnover223.38%IV-39.25%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type-0.0481Delta0.0152Gamma135.53Leverage Ratio-0.0408Theta-0.0002Rho-6.53Eff Leverage0.0030Vega
Intraday
- 5D
- 1D
News
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading
European equities traded in the US as American depositary receipts were trending modestly higher late Wednesday morning, rising 0.34% to 1,399.71 on the S&P Europe Select ADR Index. From continental E
Calliditas Therapeutics' Potential Head and Neck Cancer Treatment Meets Secondary Endpoints
Calliditas Therapeutics (CALT) said Monday that data from a phase 2 trial of its drug candidate setanaxib in combination with pembrolizumab in patients with head and neck cancer met its secondary endp
Calliditas Therapeutics Reports Data From Phase 2 Study Of Setanaxib In Combination With Pembrolizumab For Head And Neck Cancer
Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in c
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading
European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.25% to 1,364.91 on the S&P Europe Select ADR Index. From continental Europe,
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Stifel Nicolaus Sticks to Its Buy Rating for Calliditas Therapeutics (CALT)
Comments
$Calliditas Therapeutics(CALT.US$
NEWS
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...
NEWS
Calliditas Announces Positive NefIgArd Open Label Extension Results
Calliditas Therapeutics AB announced positive results from the NefIgArd Open Label Extension study, showing consistent treatment response in terms of proteinuria reduction and eGFR stabilization at 9 months for all IgAN patients. The study followed the successful Phase 3 NefIgArd study, which led to FDA approval in December 2023, and the full data set was published in The Lancet. CEO Renée...
$Calliditas Therapeutics(CALT.US$
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon c...
NEWS
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Consistent improvement in estimated glomerular filtrate rate (eGFR) with Nefecon treatment compared to placebo.
30% reduction in UPCR with Nefecon sustained over 2 years, leading to lower risk of kidney failure.
Significantly delayed time to kidney function decline events with Nefecon c...
1
The full approval of TARPEYO by the FDA is seen as a significant achievement for Calliditas, potentially paving the way for future successes. The company's projected revenue growth for 2024 indicates optimism about its financial performance.
$Calliditas Therapeutics(CALT.US$ Get some volume going!
Read more